
Equity Analysis Guide: Myriad Genetics (b) (MYGN)

Company	Ticker	Sector Industry	Quality	PAR
Myriad Genetics (b)	MYGN	Healthcare Biotechnology	60	15.8%
Current Price (12/13)				\$23.93
CAPS Rating (Rate this stock on CAPS	3)		***	r
	Ex	pected Income Statement		
Current Sales				9.0
Sales Growth Forecast				14.3%
Net Profit Margin				17.8%
Projected Shares Outstanding				68.00
EPS - Five year Forecast				\$3.11
Average P/E Ratio		16.0		
Projected Average Price		\$49.82		
Price Appreciation (Annualized)				15.8%
Annual Dividend Yield				0.0%
Projected Annual Return				15.8%
		Quality		
Financial Strength			77	19.2
EPS Stability			47	11.7
Industry Sales Growth Rate			14.4%	12.4
Industry Net Profit Margin			16.9%	13.2
Calculated Quality Rating				56.4
		Fool CAPS		
Total Players 5710utperforms			84 Underper	forms
All-Stars (177) 166Outperforms (94%)			11Underper	forms
166Outperforms (94%) Fundamental Data Updated: 12/13/2013			11Underper	forms



Quality Le	gend:
Blue	Excellent with quality greater than 80.
Green	Good with quality between 60 and 80.
Neutral	Average or below average with quality between 20 and 60.
Red	Poor with quality less than 20.
PAR Lege	nd:
Green	PAR is within the target range of MIPAR +5-10%, currently 11.1%-16.1%
Yellow	PAR is above the target range of MIPAR +10%, currently 16.1%
PAR	Projected Annual Return
MIPAR	The Manifest Investing Median PAR of all stocks in the database.

MIPAR	6.1%
Sweet Spot	11.1%-16.1%

Top in Industry:

Biotechnology		
Ticker	Quality	PAR
MYGN	60	15.8%
TECH	83	9.2%
UTHR	62	17.9%
ARNA	54	13.8%
VRTX	57	9.3%

Top in Sector:

	Healthcare	
Ticker	Quality	PAR
MR	98	17.3%
NRCIB	100	18.8%
MLAB	94	12.9%
NVO	99	11.6%
RMD	96	11.9%

Company Name Legend:	
•	Not covered by Value Line Standard Edition.
)	Uses price-to-book value for valuation purposes.
P/CF	Uses price-to-cash flow for valuation.